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Abstract: Dietary lipids have a major role in nutrition, not only for their fuel value, but also as
essential and bioactive nutrients. This narrative review aims to describe the current evidence
on nutrigenomic effects of dietary lipids. Firstly, the different chemical and biological properties
of fatty acids contained both in plant- and animal-based food are illustrated. A description of
lipid bioavailability, bioaccessibility, and lipotoxicity is provided, together with an overview of the
modulatory role of lipids as pro- or anti-inflammatory agents. Current findings concerning the
metabolic impact of lipids on gene expression, epigenome, and gut microbiome in animal and human
studies are summarized. Finally, the effect of the individual’s genetic make-up on lipid metabolism
is described. The main goal is to provide an overview about the interaction between dietary lipids
and the genome, by identifying and discussing recent scientific evidence, recognizing strengths and
weaknesses, to address future investigations and fill the gaps in the current knowledge on metabolic
impact of dietary fats on health.
Keywords: nutrigenomics; fatty acids; inflammation; gut microbiota; personalized nutrition
1. Introduction
Diet is one of the most important environmental factors able to maintain health and
prevent diseases, starting from early neonatal life with a myriad of nutritional properties,
affecting energy supply, regulatory functions, and structural roles [1,2]. During recent last
years, omics approaches, including genetics, epigenetics, and gut microbiome analyses,
have been introduced in nutrition research, providing a comprehensive picture able to
renovate molecular nutrition studies toward an advanced and systemic vision. Food has
been studied not only from a chemical prospective, but also for the capacity of metabolites
produced by food oxidation to modulate gene expression, directly (nutrigenomics) or by
epigenetics remodeling (nutri-epigenomics) [3]. However, inter-individual differences (i.e.,
the genetic variability) and environmental exposures (i.e., physical activity, drug, food
pesticide residues, etc.) contribute to produce a plethora of multifaceted effects [4]. For
these reasons, understanding molecular effects of food on human health is an ambitious
but promising goal, which could strongly impact dietary choices considering not only food
composition, but also its nutrigenomic and nutri-epigenomic properties.
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In particular, one of the aims of nutrition research is to control systemic chronic
inflammation (SCI), that negatively affects human health [5]. Since, SCI can increase
the risk of developing several diseases (i.e., metabolic syndrome, cardiovascular disease,
neurodegeneration, cancer, etc.), one major focus of nutrigenomics is to identify those foods
or food-derived metabolites that can modulate pro and anti-inflammatory genes expression.
In this context, dietary lipids can exert both pro- and anti-inflammatory effects, according
to their chemistry. Unfortunately, consumers’ dietary unhealthy habits frequently results in
a poor nutrition rich in ultra-processed food intake. However, we have a partial knowledge
of the composition of the food we daily eat [6], and of the impact that food can have on our
individual genome, several findings about nutrigenomic properties of dietary lipids from
both humans and animal models have been collected.
In this milieu, the objectives of the present narrative review are framed as follows:
(1) describe the lipid content in plant and animal-based food products; (2) outline the
molecular mechanisms associated to the pro- and anti-inflammatory responses of dietary
fatty acids; (3) summarize the main findings on nutrigenomics of dietary lipids acquired
from animal and human studies; (4) explain the mechanisms implicating dietary lipids in
the modulation of the gut microbiota compositions and metabolites production; (5) discuss
the main impact of dietary lipids on human health.
The search strategy includes the terms “nutrigenomics AND dietary lipids” or “fats
AND animal-based food products” or “fats AND plant-based food products” or “fatty
acids AND inflammation” or “fatty acids AND human health” or “dietary lipids AND gut
microbiota” or “fats AND gut metabolites” as keywords. The search has been performed
in the NCBI-PubMed database. The records have been screened for relevant information
and only papers published within the period 2010–2020 have been selected and studied.
2. Dietary Lipids: Fatty Acids in Plant- and Animal-Based Food Products
Dietary lipids’ main roles are to supply energy, provide essential fatty acids, guarantee
the required lipids for cellular structures (i.e., membranes), regulate signaling systems,
and ease the absorption of fat-soluble vitamins (A, D, E and K). According to their physic-
ochemical structure, dietary lipids exert a different nutrigenomic impact, modulating
the expression of genes involved in the control of inflammation, blood pressure, lipid
metabolism, and other metabolic responses [7–9].
Dietary lipids comprise fatty acids (FAs) and cholesterol. FAs can be free (i.e., butter,
oils, milk) or esterified in food to form triacylglycerols and other complex lipids (i.e.,
phospholipids, glycolipids, and glycoproteins). FAs differ for the length of the carbon
chains, which influence the intimate physicochemical properties, and for the absence
or the presence of one or more double bonds; based on this second feature, three main
classes exist: (i) saturated FAs (SFAs), such as palmitic acid, myristic acid, and lauric acid;
(ii) monounsaturated FAs (MUFAs), such as ω-9 oleic acid (OA); (iii) polyunsaturated FAs
(PUFAs) (Figure 1). PUFAs include two essential groups, omega-3 (or n-3 or ω-3) and
omega-6 (or n-6 or ω-6) FAs, which have to be obtained through the diet because they
cannot be synthetized by human enzymes. Amongω-3 FAs, linolenic acid (ALA; 18:3ω-3)
is mostly contained in plants (i.e., flaxseed, canola, soybean, nuts, walnuts, chia seeds, etc.),
while eicosapentaenoic acid (EPA; 20:5ω-3) and docosahexaenoic acid (DHA; 22:6ω-3) are
present mostly in fish, seafood, and marine algae. Amongω-6 FAs, linoleic acid (LA; 18:2
ω-6) is provided by seed oils, soybean, nuts, and cereals, while arachidonic acid (ARA; 20:4
ω-6) is found in poultry and eggs [10]. Land-based food chain is dominated by higher LA
than ALA; these two essential FAs give rise toω-6 andω-3 series, which have a different
impact on the inflammatory response.
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(1.4 g/100 g) [11]. Meat content in MUFAs (i.e., ω-3) is very low (0.1–0.2 g/100 g), while the 
ω-6 LA is 2.9, 3.2, and 0.8 (g/100 g) in beef, pork, and chicken breast, respectively [11]. 
However, feed background of ruminants (i.e., forage- or grass-fed containing high 
amount of ALA) significantly contributes to increase the concentration of ω-3 FAs in red 
meat [12]. Among animal-based food products, whole milk is rich in SFAs (2.2 g/100 g), 
whose content decreases in skimmed milk (0.1 g/100 g). Butter is an animal fat containing 
a large amount of SFAs (52.9 g/100 g) and cholesterol (227 mg/100 g) [11,13]; margarine, 
obtained from partially hydrogenated vegetable oils, includes less SFAs (8.5 g/100 g) than 
butter, but it is rich in trans-FAs, which increase the risk to develop cardiovascular and 
neuronal disorders [14–16]. 
Among the most commonly used edible oils, coconut oil (CO) contains the highest 
SFAs content (81.2–94%), followed by palm oil (PO) (49.7–57.5%), soybean oil (6.0–24.0%), 
olive oil (12.5–20.9%), corn oil (15–16%), walnut oil (5–17%), and sunflower oil (9–13%) 
[17]. The content in the OA, an ω-9 MUFAs, (which exerts anti-inflammatory properties 
and improve blood pressure [18–21]) decreases form olive oil (54.5–80.2%), to PO (37.3–
40.8%), corn oil (27.6–34.6%), soybean oil (15–36%), sunflower oil (16.4–27.6%, walnut oil 
(10–20%) and CO (5–10%). LA concentration increases starting from coconut oil (1–2.5%), 
to PA (9.1–11%), olive oil (4.9–21.2%), corn oil (48.8–55.3%), soybean oil (42.8–56.1%), wal-
nut oil (55–70%), and sunflower oil (60.2–72.1%). ALA content decreases from walnut oil 
(10–18%) to soybean oil (2–14%), CO (0.2–2.5%), sunflower oil (0.07–1.8%), olive oil (0.7–
1.5%), corn oil (0.6–1.49%), and PA (0.01–0.25%) [17].  
Other aspects should be considered in the evaluation of the nutrigenomic properties 
of plant- and animal-based fats: (i) the presence of bioactive compounds that contribute 
to modulate gene expression; (ii) the oil oxidative stability. For example, olive oil contains 
a large number of bioactive substances, such as polar phenolic substances (i.e., 
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V ious SFAs are supplied by both animal- (i.e., meat, seafood, milk, cheese, eggs,
etc.) and plant-based foo (i.e., oilseeds, olives, vocados, walnuts, etc.). Meat content in
SFAs depends on animal species, growth, and environme tal conditions; generally, SFAs
content decreases going from beef (6.2 g/100 g) to pork (5.4 g/100 g) and to chicken breast
(1.4 g/100 g) [11]. Meat content in MUFAs (i.e.,ω-3) is very low (0.1–0.2 g/100 g), while
theω-6 LA is 2.9, 3.2, and 0.8 (g/100 g) in beef, pork, and chicken breast, respectively [11].
However, feed background of ruminants (i.e., forage- or grass-fed containing high amount
of ALA) significantly contributes to increase the concentration of ω-3 FAs in red meat [12].
Among animal-based food products, whole milk is rich in SFAs (2.2 g/100 g), whose
content decreases in skimmed milk (0.1 g/100 g). Butter is an animal fat containing a large
amount of SFAs (52.9 g/100 g) and cholesterol (227 mg/100 g) [11,13]; margarine, obtained
from partially hydrogenated vegetable oils, includes less SFAs (8.5 g/100 g) than butter,
but it is rich in trans-FAs, which increase the risk to develop cardiovascular and neuronal
disorders [14–16].
Among the most commonly used edible oils, coconut oil (CO) contains the highest
SFAs content (81.2–94%), followed by palm oil (PO) (49.7–57.5%), soybean oil (6.0–24.0%),
olive oil (12.5–20.9%), corn oil (15–16%), walnut oil (5–17%), and sunflower oil (9–13%) [17].
The content in the OA, an ω-9 MUFAs, (which exerts anti-inflammatory properties and
improve blood pressure [18–21]) decreases form olive oil (54.5–80.2%), to PO (37.3–40.8%),
corn oil (27.6–34.6%), soybean oil (15–36%), sunflower oil (16.4–27.6%, walnut oil (10–20%)
and CO (5–10%). LA concentration increases starting from coconut oil (1–2.5%), to PA
(9.1–11%), olive oil (4.9–21.2%), corn oil (48.8–55.3%), soybean oil (42.8–56.1%), walnut oil
(55–70%), and sunflower oil (60.2–72.1%). ALA content decreases from walnut oil (10–18%)
to soybean oil (2–14%), CO (0.2–2.5%), sunflower oil (0.07–1.8%), olive oil (0.7–1.5%), corn
oil (0.6–1.49%), and PA (0.01–0.25%) [17].
Other aspects should be considered in the evaluation of the nutrigenomic properties
of plant- and animal-based fats: (i) the presence of bioactive compounds that contribute to
modulate gene expression; (ii) the oil oxidative stability. For example, olive oil contains
a large number of bioactive substances, such as polar phenolic substances (i.e., hydroxy-
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tyrosol and derivatives like oleuropein complex, tyrosol) and α-tocopherol, which plays
a key role in the health promotion and oil stability [22]. Another example is the thymo-
quinone, contained in Nigella sativa oil, which contributes to modulate the noteworthy
anti-inflammatory properties of this oil, which resulted to be quite similar to olive oil in
low-grade inflammation models [23–25]. To increase their healthy properties, some foods
have been also fortified with ω-3 PUFAs (i.e., egg sticks, hen eggs, dahi, chicken-meat,
milk, etc.) [26–30]. Moreover, research has identified also other kinds of vegetable oils
that could represent a suitable source of healthy lipids. These includes oils derived from
cucumber, tomato, pumpkin or carrot seeds, which contain different profiles of FAs; for
instance, OA is largely contained in carrot seed oil (78.97 g/100 g of total FAs) [31].
Another significant aspect to consider is the oxidative status of oils and of the other
dietary lipids, which depends on their unsaturated FAs content (i.e., the presence of
double bonds is associated to a faster oxidation rate). For example, LA, which has two
double bonds, shows an oxidation rate ten times higher than OA, which has only one
double bond [32]. Hydroperoxides and malondialdehyde (MDA) can be produced during
technological processing, light exposure, oxygen, and temperature storage, as well as
due to cooking; lipid oxidation decreases the quality of dietary FAs and their chemical,
sensory and structural properties (i.e., membrane phospholipids) [33–35]. For all these
reasons, vegetal- and animal-based food should be evaluated also considering both intrinsic
components (i.e., FAs composition, antioxidants, water, etc.) and external factors (i.e., light,
temperature, oxygen), which contribute to preserve their original naïve composition. For
example, the high quality of olive oil, with a lower oxidative index in respect to others [32],
depends on the high concentration of MUFAs and the low PUFAs content; this is an
additional value over and above the bioactive substances contained in the unsaponifiable
fraction, which also has a well-balanced saponifiable fraction, rich in OA and poor in SFAs.
Considering the metabolic and functional roles of dietary lipids, from 20 to 35% of
the total energy should be obtained from fat. For each type of fat, the recommendations
are as follows: SFAs < 10%, PUFAs 5–10%, of which ω-6 PUFAs 4–8% and ω-3 PUFAs
0.5–2%, trans-FAs < 1% and cholesterol < 300 mg, according to accepted dietary recommen-
dations [36].
In summary, plant- and animal-based foods contribute to modulate molecular re-
sponses according to their chemical composition and stability; whether prefer plant- or
animal-based food has been the object of study for a long time, and research on large
cohorts of middle-age adults supports the positive impact of a higher adherence to a plant-
based diet due to the presence of bioactive compounds able to reduce the risk of mortality
(i.e., cardiovascular disease mortality (−19%), all-cause mortality (−11%)) [37]. Multiple
studies in different models (i.e., cell lines, preclinical and human studies) have provided a
wealth of information on the molecular basis of dietary lipids’ impact on gene expression.
Henceforth, the following sections describe these data in order to give a comprehensive
picture of the nutrigenomic impact of dietary lipids.
3. Dietary Lipids Bioavailability, Bioaccessibility, and Toxicity
As well as for other bioactive food compounds, the nutritional effect of lipids depends
on their release in the gastrointestinal tract, intestinal absorption, and metabolism (i.e.,
their bioaccessibility and bioavailability). Lipids bioavailability refers to the fraction of the
ingested lipids that eventually reaches the systemic circulation, to be later distributed to
tissues and organs, where it may be either stored, utilized, or excreted. However, not the
whole lipid cargo of a meal is bioavailable to exert a biological function. Indeed, only the
bio-accessible lipid fraction, which is the one released from the food matrix, is available for
intestinal absorption. Hence, for lipids, the possibility to exert a biological effect is strictly
dependent on their bio-accessibility (Figure 2) [38].
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Ra írez et al. escri e t e i esti ilit f s is influenced by lipid source and
content of a meal, dietary fibers, host animals, and other molecules (e.g., mucilage and
cyanogenic glycosides in flaxseed) [39]. For instance, it is well documented that the
digestibility of lipids inversely correlates ith the dietary fiber content of a eal [40]. Also,
the total fat content of a meal can modulate the bioavailability of dietary FAs, mainly
through the stimulation of pancreatic juice secretion and the activation of pancreatic lipases,
which makes dietary FAs more accessible. The role of the meal fat content is especially
crucial for essential ω-3 PUFAs, in particular for dietary ALA, whose conversion rate into
physiologically active EPA and DHA is very limited: even though data from literature
may slightly differ, approximately 5% of ALA is converted to EPA and less than 0.5%
to DHA [41]. Moreover, it was already known that the conversion rate is dependent on
certain physiological states and on the concentration of ω-6 PUFAs or other fats [42]. In
particular, previous evidence suggested that with a background diet rich in saturated fats,
the conversion of ALA to EPA is around 6%, while approximately 3.8% ALA is converted
to DHA. Instead, with a background diet rich inω-6 PUFAs, this conversion decreases by
40 to 50% [43]. However, ALA conversion seems to be unaffected by the ω-6/ω-3 ratio,
and being dependent only on their absolute amounts in the diet [42]. Lawson and Hughes
showed that ω-3 PUFAs absorption rate can be increased three-fold when co-ingested
with a high-fat meal relative to a low-fat meal [44,45]. Interestingly, the ECLIPSE studies
[Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation] have
proved that a novel free FAs (FFAs) formulation for ω-3 supplements (OM-3 FFA) exhibits
a 4-fold greater bioavailability in overweight patients either in a single dose (4 g) [46,47] or
over a two-week period under low-fat dietary intake [48]. This might help in subjects with
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hypertriglyceridemia that need to maximize the intestinal absorption of EPA and DHA,
while maintaining their total dietary fat intake low.
Several studies proved that not only the composition, but also the structure (solid
or liquid) of the food matrix is an important modulator of dietary fats accessibility. An
in vitro study on microencapsulated tuna oil showed that either the way of ingestion
or the chemical formulation strongly affect the release of EPA and DHA from tuna oil
during digestion [49]. In vitro digestion of tuna oil in the form of neat microencapsulated
tuna oil powder (25% oil loading) or in food matrices (orange juice, yogurt, or cereal bar)
fortified with microencapsulated tuna oil powder (fortification was equivalent to 1 g of
tuna oil per recommended serving size), showed that the percentage of EPA and DHA
released from tuna oil was greater (73.2–78.6%) for neat powder, fortified orange juice, and
yogurt compared to the fortified cereal bar (60.3–64.0%), proving that the food matrix, its
structure (e.g., solid versus liquid), and its composition (greater fiber content of the cereal
bar) may affect in vitro digestion of microencapsulated tuna oil powder [49]. An in vivo
study, based on three matrices having the same composition but different structures (DHA-
enriched egg in the form of omelet, hard-boiled egg, and mousse) found that the egg in the
form of omelet was the most efficient vector for delivering DHA into systemic circulation
(33.3 ± 3.6 µg/mL and 17.9 ± 3.7 µg/mL at 10 and 24 h after feeding, respectively),
further stressing the impact of food matrix structure on DHA bioavailability [50]. Lastly,
differently structured food products can lead to different profiles of postprandial lipemia.
For example, for dairy products, Lamothe et al. showed that the fatty acid release in the
intestinal phase is faster when the cheese matrix derives from homogenized milk [51]. Also,
the cheese’s composition, viscosity, and structure (more or less solid) have an impact on
the kinetics of digestion of the lipids from cheeses and can affect the peak of postprandial
triglyceridemia [52]. Specifically, the denser and more cohesive the cheese matrix structure,
the lower the rate gastric digestion of lipids [53].
In addition, several human studies have focused on the role of the chemical struc-
tures of lipids on Fas bioavailability [44]. Over 90% of dietary lipids are esterified to
triacylglycerol (TAGs), but they can only be absorbed when released from the TAGs as
non-esterified FAs (FFAs) or as 2-monoacylglycerols (2-MAGs) after digestive lipolysis [54].
The rate at which FAs are released from TAGs during lipolysis inversely correlates with
their chain length, and also depends on their intramolecular structure on the glycerol
backbone (internal sn-2 position, external sn-1 and sn-3 positions). Thus, digestive lipases
preferentially hydrolyse FAs esterified on sn-1,3 positions of glycerol backbone, but when
TAGs contain long-chain FAs in these positions, their hydrolytic activity decreases. For
instance, long-chain saturated FAs, such as palmitic acid and stearic acid, are mainly bound
in the sn-1 and sn-3 positions of TAGs, but exhibit poor bioavailability because they tend
to form complexes in presence of divalent ions (Ca2+ and Mg2+), resulting in the formation
of insoluble soaps in the small intestine that can be lost in the stools [54,55]. Instead, when
PUFAs are esterified in the sn-1 and sn-3 positions of TAGs with double bonds close to
the carboxyl group, the hydrolytic activity of lipases decreases because of steric hindrance
problems, with an impact on PUFAs bioavailability [54]. Conversely, PUFAs esterified at
the sn-2 position of TAGs appear to be more efficiently absorbed. For example, supplemen-
tation of human adults with fish oil, which has DHA mostly on sn-2 position and EPA on
the sn-1 and sn-3 positions, resulted in more rapid incorporation of DHA in plasma TAGs
than EPA [56]. Coherently, a six-month supplementation of identical doses of EPA+DHA
resulted in a faster and higher increase in the ω-3 index (i.e., the percentage of EPA+DHA
in red blood cell membranes) when consumed in the form of triacylglycerides than as
ethyl esters (EEs) [57]. Studies on the kinetics of ω-3 PUFAs confirmed the following
trend for bioavailability: FFAs > TAGs > diacylglycerol (DAGs)\MAGs > EEs [58–60],
although recent findings [61] question the previously stated greater bioavailability of TAGs
compared to EEs [62], while information on the bioavailability ofω-3 PUFAs esterified to
phospholipids is so far poor and inconclusive [63,64].
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Lastly, PUFAs’ bioavailability and transformation can be also affected by the gut
microbiota. In fact, some microbial species, such as Butyrivibrio fbrisolvens, Clostridium
proteoclasticum, or Lactobacillus plantarum play a crucial rule in the transformation ofω-6\ω-
3 PUFAs into conjugated FAs that may further undergo hydrogenation to saturated FAs,
reducing the amount of the bioavailable unsaturated fraction [65].
In addition to bioavailability, another aspect to mention before discussing the molecu-
lar effects of lipids is lipotoxicity. Lipotoxicity arises as a consequence of the accumulation
of biosynthetic lipid intermediates, such as ceramides and diglycerides, within non-adipose
tissues, and induces endoplasmic reticulum stress, inflammation, mitochondrial dysfunc-
tion, and ultimately apoptosis [66]. Pancreatic β-cells are among the most affected cells,
whose impaired insulin secretion results in the development of insulin resistance, T2DM
or other obesity-related pathologies, such as cardiovascular diseases and the metabolic
syndrome [67–70]. Lipotoxicity may also affect other organs, such as kidney, liver, heart
and skeletal muscle, and clinical manifestations are renal dysfunction, anemia, heart failure,
and sarcopenia [71]. To mitigate the detrimental effects of ectopic lipid accumulation,
lipid-lowering drugs supported by suitable dietary changes may be valid tools. In this
regard, recent studies have shown that soy proteins and soy isoflavones are able to decrease
lipotoxicity by modulating insulin secretion and lowering ceramides accumulation [72,73].
Another mechanism by which lipid imbalance turns out to be toxic is lipid peroxidation.
Lipid peroxides are highly reactive compounds, which trigger many pathological states
including inflammation, cancer, neurodegenerative disease, as well as ocular and kidney
degeneration. They result from enzymatic (cyclooxygenase (COX), cytochrome P450 (CYP),
and lipoxygenase (LOX)) and non-enzymatic (“Fenton Chemistry”) peroxidation reactions
of lipids, preferentially PUFAs. Lipid peroxides not only alter the assembly, composition,
structure, and dynamics of cell membranes, but can exhibit additional toxicity with their
degradation products: hydroxy acids and reactive aldehydes, like and 4-hydroxynonenal (4-
HNE) and MDA, are able to propagate further generation of reactive oxygen species (ROS)
or crosslink DNA and proteins, resulting in multiple pathologies and cell death [74–77].
To conclude, Fas bioavailability, bioaccessibility and toxicity contribute to determine
their role as regulatory and bioactive molecules.
4. Crosstalk between Fatty Acids and Inflammation
FAs, synthesized or metabolized from dietary sources, serve mainly as structural com-
ponents of cells and energy substrates; however, increasing evidence have demonstrated
an important role as mediators of inflammation, with downstream effects depending on
their nature [78,79]. The effect of FAs on inflammatory responses derives from their incor-
poration into cell membrane phospholipids. Different lipid mediators may be generated
from phospholipids, which can boost or fight against inflammation. Based on that, lipid
mediators deriving fromω-6 PUFAs are considered pro-inflammatory and are associated
with the pathogenesis of inflammatory processes [80]. A direct link with inflammation
is provided by LA, a common dietaryω-6 PUFAs. LA can be converted to ARA, a major
component of membranes phospholipids, which acts as a substrate for COX, LOX, and CYP
enzymes to yield eicosanoid mediators, such as hydroperoxyeicosatetraenoic acid (HPETE),
prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins. Given its
abundance in cell membranes, ARA is the major substrate for eicosanoids production,
which explains why it is considered proinflammatory. Eicosanoids are oxidized lipid
derivatives, which control initiation, magnitude, and duration of inflammation, acting
usually via G protein-coupled receptors (GPCRs) [81]. However, not all eicosanoids have
pro-inflammatory effects, such as those derived fromω-3 PUFAs [82]. In this regard, EPA
and DHA, resulting from chemical modifications of ALA, the major representative of
ω-3 PUFAs, give rise to eicosanoids with primarily anti-inflammatory or pro-resolving
functions [82]. Because of structural differences compared to those derived from ARA,
EPA-derived eicosanoids bind with lower affinity to eicosanoid receptors resulting in a
weaker inflammatory response [83]. Moreover, EPA and DHA give rise to pro-resolving
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eicosanoid mediators, the so-called resolvins, protectins, and maresins, which accelerate
the resolution of inflammation [84,85], inhibiting immune cells migration, matrix metallo-
proteinases synthesis, and the release of inflammatory cytokines, like interleukine (IL)-1α,
IL-1β, IL-6, IL-8, IL-12, tumor necrosis factor α (TNFα), interferon γ (IFNγ), and many
more [83]. The main mechanism by whichω-3 PUFAs block the cytokines storm is through
the suppression of the nuclear factor kappa B (NF-κB) inflammatory signaling [86] NF-κB
impairment is firstly mediated by the activation of the peroxisome proliferator-activated
receptor γ (PPAR-γ), a transcription factor that physically interferes with NF-κB translo-
cation to the nucleus, preventing pro-inflammatory cytokines release [87]. Moreover,ω-3
PUFAs prevent the activation of Toll-like receptors (TLRs), in particular TLR4, which is the
starting point for NF-κB activation and, lastly, they initiate an anti-inflammatory signaling
cascade by binding to GPR40 and GPR120 [88–90]. The different effects of dietary ω-6 and
ω-3 PUFAs on the inflammatory cascade shed light on the importance of keeping a low
ω-6/ω-3 ratio (4:1), in order to prevent or mitigate inflammatory-based pathologies, such
as obesity, T2DM, arthritis, and others [91–93].
Anti-inflammatory properties have also been attributed to MUFAs [94]. MUFAs, such
as oleic acid or palmitoleate, inhibit the formation of nucleotide-binding and oligomeriza-
tion domain-like receptor, leucine-rich repeat, and pyrin domain-containing 3 (NLRP3)
inflammasome, which is important for the production of mature inflammatory cytokines
(i.e., IL-1β and IL-18) [7]; moreover, they maintain 5’AMP-activated protein kinase (AMPK)
activity, which reduces the inflammatory response [95]. As PUFAs, MUFAs do not seem
to activate TLR4 signaling [96], which instead, is one of the main mechanisms by which
SFAs promote inflammation. Indeed, a proinflammatory effect has been attributed to
SFAs, especially lauric acid, because of their effect on TLR2 and TLR4 signaling path-
ways [96,97]. SFAs trigger the dimerization and translocation of TLR2 or TLR4 into lipid
rafts of plasma membranes, activating downstream signal transduction pathways in mono-
cytes/macrophages, adipocytes, skeletal muscle cells, and pancreatic β cells [97,98]. Upon
interaction with TLRs, SFAs activate the myeloid differentiation primary response 88
(MyD88)-dependent signaling cascade, culminating with the activation of the two major
inflammation-related signaling routes in cells, NF-κB and mitogen-activated protein kinase
(MAPK) pathways [97]. Both result in increased expression and release of pro-inflammatory
cytokines and chemokines. These mediators induce local or systemic inflammation, also
helped by the massive release of ROS upon activation of nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase [99]. The signaling cascade activated by ROS and other stress
molecules, like ATP and ceramides, leads to the assembly of the NLRP3 inflammasome,
with the subsequent release of inflammatory cytokines [100,101], which, on the contrary, is
counteracted by dietary MUFAs andω-3 PUFAs [7,102]. In addition, SFAs may also induce
the release of inflammatory cytokines in a MyD88-independent manner, via the activation
and nuclear translocation of interferon regulatory factor 3 (IRF3), or reinforcing NF-κB
activation [97].
However, SFAs must not be demonized in toto. A subset of SFAs, the so-called short
chain fatty acids (SCFAs) are known for their positive regulatory effect on the immune
responses. SCFAs are the end products of anaerobic fermentation of dietary fiber and
resistant starches by colonic bacteria strains, with the main members being acetate, propi-
onate, and butyrate. Recent evidence shows that SCFAs play an anti-inflammatory role
through GPCRs, in particular GPR41 and GPR43, and via inhibition of histone deacetylases
(HDACs) [103]. The binding of SCFAs to GPCRs prevents NF-κB activation [104] and
up-regulates the expression of anti-inflammatory IL-10 via HDAC inhibition [105–107].
Although SCFAs anti-inflammatory role appears evident, some studies have found that
the same pathway mediated by GPCRs may also trigger SCFAs-induced pro-inflammatory
responses [108,109].
Moreover, other experimental studies have demonstrated that the effect of lipids
can be modulated by other dietary components. For example, a diet containing SFAs
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supplemented with polyphenols (i.e., epigallocatechin gallate, resveratrol) shows a reduced
pro-inflammatory response [110–112].
Remarkably, it has been found that the deficiency of NLRP3 inflammasome reduces
the negative impact of a high fat diet (HFD) also through changes in the gut microbiota
composition, supporting a pivotal role of this pathway in regulating the effect of fatty acids
on inflammation also through the microbiome (see Section 6 for details) [113].
In conclusion, FAs exposure and FAs composition of cellular membranes profoundly
influence cellular functions, but the final effect is complex and is the resultant of the whole
composition of the diet. Overall, the types of FAs consumed with diet are of pivotal
importance for the modulation of inflammatory processes via the activation or repression
of key intracellular signaling pathways, with MUFAs, ω-3 PUFAs, and SCFAs mainly
triggering anti-inflammatory responses, and SFAs or ω-6 PUFAs leading towards a pro-
inflammatory state (Table 1).
Table 1. Major molecular mechanisms explaining the dietary FAs modulation of the inflammatory response.
Fatty Acids Pro-Inflammatory Effect Anti-Inflammatory Effect Other Effects References
SFAs
TLR2/TLR4 signaling pathways [96–98]
MyD88-dependent NF-κB and
MAPK activation















Inhibition of NF-κB activation [104]





Downregulation of IL-1β and IL-18
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Table 1. Cont.
Fatty Acids Pro-Inflammatory Effect Anti-Inflammatory Effect Other Effects References
ω-3 UFAs
EPA/DHA-derived eicosanoids, such
as resolvins, protectins, and maresins,
induce a milder inflammatory
response and accelerate resolution of
inflammation
[82–85]
NF-κB signaling suppression via
PPAR-γ activation, impairment of









5. Nutrigenomics of Fats: Evidence from Animal Studies
Experimental studies in animal models, conducted under ethical conditions, have pro-
vided the opportunity to evaluate molecular effects of various lipid mixtures or individual
molecules, which could not be otherwise obtained from human studies. Indeed, animals
fed with SFAs, MUFAs, or PUFAs showed differences in the activation of inflammatory
pathways in healthy and unhealthy conditions, as well as contributed to elucidate the
molecular mechanisms by which dietary lipids can modulate these metabolic pathways
through gene expression changes.
For example, obese mice fed with a HFD (29.64% SFA, 4.86% PUFA) for 25 weeks
developed a severe early psoriasiform skin inflammation, which was dependent on FFAs
levels but independent of fat mass extension, blood glucose levels, and adipose tissue-
derived mediators. SFAs, which were increased by the HFD, were unraveled to sensitize
myeloid cells, resulting in an amplified proinflammatory immune response to TLRs stimuli,
which in turn augmented keratinocyte activation. On the other hand, dietary reduction of
SFAs (0.73% SFA, 3.73% PUFA) dampened psoriasiform inflammation [114]. In another
animal model, non-obese non-diabetic mice gavaged for one day with PO (2 g/kg body
weight), included in a low-fat diet (LFD) (13% of calories derived from fat, 17 kJ/g), showed
an increase in hepatocellular lipids concentrations, lipid oxidation, and insulin resistance.
Moreover, mouse transcriptomics revealed that PO differentially regulates pathways,
including members of the TLRs and PPAR families, and NF-κB and TNF-related weak
inducers of apoptosis [115]. Other experimental animal studies suggested that dietary SFAs
(99.8% fat for 18 weeks) may directly promote the development of heart failure by inducing
lipotoxicity [116]. SFAs, like lauric acid (C12:0) and myristic acid (C14:0), induced oxidative
stress and myocardial fibrosis even in the absence of pressure overload if supplemented
to a standard chow diet supplemented with 0.2% cholesterol and 10% CO diet for eight
weeks ad libitum in female C57BL/6 mice. This supplementation enhanced myocardial
fibrosis, reduced capillary density, and increased myocardial cell apoptosis in postoperative
pathological myocardial hypertrophy. Overall, it aggravated the pressure overload-induced
cardiomyopathy [117]. High intake of SFAs, especially in presence of carbohydrates, has
been shown to increase blood cholesterol, TG, and low-density lipoprotein cholesterol
(LDL-C), which are associated to arterial lumen stenosis, atherosclerosis development, and
increased risk of coronary heart disease. Furthermore, animal studies also correlated HFD
(60% pork lard for 16 weeks) to cognitive impairments [118].
Interestingly, the nutrigenomic effects of SFAs have been investigated and strongly
differed from those of MUFAs. SFA-HFD containing 45% kcal palmitic acid and MUFA-
HFD containing 45% kcal OA were fed to the eight to nine-week-old male C57BL/6 mice
for 24 weeks. Despite an increased prevalence of obesity being observed in both HFD-
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contained groups, adipose IL-1β inflammation and insulin resistance were significantly
lower in MUFA-HFD mice compared with the SFA-HFD group. A different regulation of IL-
1β production was observed; SFA-HFD induced pro-IL-1β and NLRP3-mediated activation
through the down-regulation of AMPK. On the contrary, MUFA-HFD suppressed IL-1β
activation via AMPK-mediated NLRP3 [7]. Compared with SFA-HFD, this bi-directional
regulation of AMPK and IL-1β was mainly identified in the adipose tissue, where MUFA-
HFD retained adipose AMPK and weakened the activation of IL-1β. In another study, LFD
and SFA-HFD (45% kcal PO) were used to feed seven to nine-week-old male C57BL/6J
mice for 32 weeks consecutively. At the same time, another group of mice was fed with SFA-
HFD for 16 weeks and then switched to MUFA-HFD (45% kcal sunflower oil) for another
16 weeks (SFA-to-MUFA-HFD). In SFA-HFD group, the expression of genes involved in
β-cell differentiation, proliferation, and identity (such as Ins2, Nkx6.1, Ngn3, and Rfx6, as
well as Pdx1 and Pax6) was significantly reduced in pancreatic islet; this SFA-HFD-induced
down-regulation was related to the impairment of cell functions. Interestingly, SFA-to-
MUFA-HFD reduced hyper-insulinemia, pancreatic inflammation, and the progression
of β-cell function impairment induced by SFA-HFD, which may mediate its effects in an
IL-1β-AMPK-dependent manner [119]. This outcome highlights how the substitution of
SFAs with MUFAs can restore impaired cellular responses. Indeed, other animal studies
also showed that the detrimental effects of an unbalanced intake of dietary lipids can be
reversed. In a study protocol, 12 week-old male C57BL/6 J mice were fed either a LFD or
HFD (containing either 10 or 60% of the total caloric intake from fat, for 3 days, 1 week, or
2 weeks); one group of mice was fed the HFD for one week and then returned to the LFD
for a further week. Results showed that after three days, one week, and two weeks, the
HFD induced changes in the hippocampal proteins involved in metabolism, inflammation,
cell stress, cell signaling, and cytoskeleton. However, the replacement of the HFD after
one week by a LFD for a further week resulted in a partial recovery of the hippocampal
proteome [120].
Concerning PUFAs, recent findings have shown thatω-3 and derivatives (0.31% or
1.25% of DHA for 4–5 weeks) can reduce the stimulation of inflammatory factors and
promote the regression of inflammation during cardiovascular processes [121]. Nine-week-
old male C57BL/6 ApoE−/− mice were fed a HFD containing 20% lard for four weeks, and
then fed with both 1% dietary DHA incorporated into phospholipids (DHA-PL) and EPA
incorporated into phospholipids (EPA-PL) for another eight weeks. The results showed that
DHA-PL and EPA-PL could markedly reduce the atherosclerotic lesions in ApoE−/− mice.
EPA-PL significantly reduced serum and liver lipid levels by mediating mRNA and protein
levels of genes involved in hepatobiliary sterol metabolism, while the transcription of TNF-
α, IL-6, and IL-1βwas decreased by DHA-PL treatment [122]. The DHA-PL exerted mainly
anti-inflammatory functions, while the EPA-PL was able to improve lipid metabolism in
atherosclerosis. To study whether the anti-atherosclerotic effect of EPA-rich fish oil partly
depends on the chemical group atω-3 position, the 18–19 week-old male ApoE−/− mice
(C57BL/6J background) were used and clustered into three groups. In the model group,
animals were fed with a HFD, while in the two study groups, animals were fed with a HFD
containing 1% EPA-PL or 1.1% EPA incorporated into triglycerides (EPA-TG) (providing
equal amounts of EPA) for 8 weeks. Compared with the control group, both EPA-PL
and EPA-TG showed a reduction in the aortic atherosclerotic lesion area and inhibition
of inflammatory markers in the aorta and circulation, with a better effect in presence of
EPA-PL than EPA-TG. It should be noted that the serum and liver lipid levels of EPA-PL
were lower than those of the model group, while EPA-TG only reduced the liver TG level.
It has been proposed that EPA-PL has some initial advantages over EPA-TG in terms of
bioavailability and therapeutic efficacy, which may be due to their structural differences at
the ω-3 site [123]. In addition,ω-3 PUFAs can reduce blood pressure in rats, and the effect
may depend on the membrane of the ion channels [124,125]. Due to positive effects on
vascular function and blood pressure, but also due to their nutrigenomic properties,ω-3
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PUFAs (EPA 3.7 g/kg/day and DHA 3 g/kg/day for 20 weeks) are considered promising
anti-atherosclerotic agents [126,127].
In addition, ω-3 PUFAs can play an important role in central metabolism. Intrac-
erebroventricular infusion of resolvin D1 (10 ng) and resolvin D2 (10 ng), bioactive lipid
mediators generated from theω-3 PUFAs DHA and EPA, produced antidepressant effects
in male BALB/c mice (8–12 weeks old) via the mammalian target of rapamycin complex
1 signaling pathway, at the medial prefrontal cortex and dentate gyrus, which are important
brain regions for these antidepressant effects [128]. Wen et al., studied in an animal model
of Alzheimer’s disease (AD), obtained treating male Sprague Dawley rats with Aβ1-40,
the protective effect of low (150 mg/kg body weight) and high (300 mg/kg body weight)
doses of EPA-PL for 27 days. The results showed that both low and high dose of EPA-PL
improved cognitive performance in Morris Water Maze in AD rats [129]. Furthermore,
treatment with EPA-PL increased the time of target phase and the numbers of crossing plat-
form. Meanwhile, EPA-PL groups also significantly decreased the level of MDA, apoptosis,
hyper-phosphorylated Tau, CD11b, glial fibrillary acidic protein (GFAP), IL-1β, TNF-α,
and increased the level of SOD in the brain of Aβ1-40-induced rats [129].
Finally, effects of ω-3 PUFAs on DNA methylation in tumors have also been ob-
served [130,131]. Colorectal cancer (CRC) rat model was developed using N-methyl
phosphite nitrourea, and six-week-old rats were fed with ω-3 PUFAs (1 g/kg body weight)
for 12 weeks. The results showed that tumor incidence inω-3 treated rats was much lower
than in CRC model rats, suggesting a significant protective role ofω-3 PUFAs. Furthermore,
5-methylcytosine content inω-3 PUFAs treated rats was higher than in CRC model rats,
suggesting that ω-3 PUFAs might regulate cytosine methylation. Therefore, it has been
hypothesized thatω-3 PUFAs could inhibit tumor growth through the regulation of DNA
methylation [132]. Indeed, despite some contrasting findings [133,134], the involvement
of epigenetic pathways in the mediation of the molecular effects of HF diets has been
described. For example, methyl donor supplementation containing 5 g/kg diet of betaine,
5.37 g/kg of choline, 5.5 mg/kg of folic acid, and 0.5 mg/kg of vitamin B12 in HFD-fed
for eight weeks ad libitum Wistar rats prevented the HFD-induced fat accumulation in
the liver and modified mRNA hepatic profile, as well as the methylation of specific gene
promoters [135]. Interestingly, it has been demonstrated that detrimental effects of HFD
can be reversible, at the level of both the epigenotype and the phenotype [136].
In conclusion, animal studies highlight that dietary fatty acids not simply are a major
energy source for the body, but also contribute to modulate various biological responses
accordingly to their chemical features (Table 2).
Table 2. Impact of dietary fatty acids on gene mediated inflammatory responses/outcomes: studies in animal models.
Fatty Acids Pro-InflammatoryEffect
Anti-Inflammatory
Effect Other Effects References
PO
(2 g/kg body weight)
increase LOX and insulin
resistance [115]
HFD
(29.64% SFAs, and 4.86%
PUFAs)













reduce oxidative stress and
myocardial fibrosis [117]
HFD (60% pork lard) IL-6, TNF-α, MCP-1 disrupt cognition [118]









and the immune system
[120]
MUFA-HFD (45% kcal
(OA)) NLRP3, IL-1β, IL-18 improve insulin sensitivity [7]
MUFA-HFD
(45% kcal sunflower oil) IL-1β, IL-6 attenuate hyperinsulinemia [119]
PUFAs
(0.31% or 1.25% of DHA)
reduce heart rate and
arrhythmia vulnerability [121]
DHA-PL, EPA-PL








MCP-1 regulate cholesterolmetabolism [123]









alleviate oxidative stress, and
hyper-phosphorylated tau [129]
ω-3 PUFAs
(12% fish iol) mtDNA methylation [130]
ω-3 PUFAs
(0.5% EPA and DHA) DNA methylation [131]
ω-3 PUFAs
(1 g/kg body weight) DNA methylation [132]
6. Nutrigenomics of Fats: Evidence from Human Studies
Growing evidence has shown that FAs may exert many of their biological effects by
regulating the activity of several transcription factors [137]. For example, ω-3 FAs can
influence the expression of several genes involved in lipid and carbohydrate metabolism,
thermogenesis, and inflammatory processes by inducing sterol regulatory element binding
proteins (SREBPs), PPARs, carbohydrate response element binding protein (ChREBP), and
NF-κB [138].
As aforementioned, ω-3 PUFAs are natural PPARs ligands. In this context, a short-
term DHA-rich fish oil supplementation (2400 mg/day for 8 weeks) increased PPARγ
activity in peripheral blood mononuclear cells (PBMCs) of subjects with T2DM compared
to placebo, improving lipid metabolism and energy homeostasis [139]. In agreement with
such trial, the intake of ω-3 FAs from flaxseed oil (2 × 1000 mg/day, containing 400 mg
α-linolenic acid, for 6 weeks) induced upregulation of PPARγ and low-density lipoprotein
receptor (LDLR) genes and downregulation of IL-1 and TNF-α in PBMCs of subjects with
gestational diabetes compared to placebo. In addition,ω-3 supplementation also improved
glycemic and lipid profiles, inflammatory markers, and oxidative stress when compared
to placebo [140]. Moreover, another study demonstrated that supplementation withω-3
PUFAs (2700 mg/day) enhanced nuclear factor erythroid 2-related factor 2 (NRF2) gene
expression in PBMCs of subjects with T2DM [141]. NRF2 is a transcription factor that
regulates the expression of antioxidant proteins that protect against oxidative damage
triggered by injury and inflammation [142].
Regarding Parkinson disease, supplementation with 1000 mg/day ofω-3 FAs from
flaxseed oil and 400 IU/day of vitamin E for 12 weeks significantly improved gene
expression of TNF-α, PPARγ and LDLR, but did not affect IL-1 and IL-8 compared to
placebo [143]. Additionally, supplementation with 50,000 IU of vitamin D every two weeks
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plus 2000 mg/day ofω-3 FAs from fish oil for 12 weeks also presented beneficial effects
on gene expression of IL-1 and vascular endothelial growth factor (VEGF) among women
with polycystic ovary syndrome [144].
Genes involved in lipid metabolism were differentially expressed in PBMCs depending
onω-3 andω-6 plasmatic levels and on the ratio of SFAs to PUFAs in healthy subjects [145].
In subcutaneous adipose tissue of subjects with obesity, high medium-chain-SFAs diet
led to upregulation of genes related to citric acid cycle and oxidative phosphorylation,
and downregulation of genes related to complement system and inflammation [146].
Moreover, the replacement of SFAs with PUFAs induced upregulations of liver X receptor-
alpha (LXRA) and LDLR, while the expression of several LXRA target genes and genes
involved in inflammation was downregulated in PBMCs of healthy subjects with moderate
hypercholesterolemia [147]. Taking all this information together, diet rich inω-3 may be
beneficial for human health. However, further studies are necessary to elucidate theω-3
effects in the pathogenesis of several diseases [138].
Mediterranean diet (MedDiet) has been proven to be highly effective in the prevention
of cardiovascular diseases and cancer and in decreasing overall mortality. In this context,
MedDiet, especially if supplemented with extra virgin olive oil (EVOO), can exert health
benefits through inducing changes in gene expression in pathways associated with cardio-
vascular risk [148]. Additionally, MedDiet enriched in MUFAs with EVOO can module
the postprandial antioxidant profile, and the expression of proinflammatory and oxidative
stress-related genes, including NF-kB p65, monocyte chemoattractant protein-1 (MCP-1),
TNF-α, NF-κB inhibitory α (IkBα), SOD1, upstream transcription factor 1 (USF1), and cata-
lase [149,150]. The consumption of a functional VOO enriched with olive oil (250 mg/kg)
and thyme phenolic compounds (250 mg/kg) upregulated the expression of key choles-
terol efflux regulators (CYP27A1, CAV1, LXRB, RXRA) and nuclear receptor-related genes
(PPARb/γ) [151].
Moreover, a study on 36 representative individuals selected within the PREvención
con DIeta MEDiterránea (PREDIMED—Navarra) trial showed that nuts and EVOO were
able to change the DNA methylation profile of several genes in peripheral blood leuko-
cytes, with potentially beneficial effects for health (concerning genes related to intermediate
metabolism, diabetes, inflammation, and signal transduction) [152]. This evidence con-
tributes to explain the role of MedDiet and fat quality on health outcomes [153].
On the basis of gene-dietary fat interaction, several single nucleotide polymorphisms
(SNPs) modulate the effects of certain dietary factors or food preferences, and the main
results are shown in Table 3. Among these genes, the most studied ones are adiponectin,
C1Q, and collagen domain containing (ADIPOQ), apolipoproteins, C-reactive protein
(CRP), fatty acid desaturase 1 (FADS1), fatty acid desaturase 2 (FADS2).
The ADIPOQ gene encodes for the adiponectin protein, which exerts anti-inflammatory,
antioxidant, and insulin sensitizer effects [154]. Several SNPs in ADIPOQ gene have been
associated with serum adiponectin levels (Table 3), interacting with dietary FAs [155–157].
Additionally, the rs2241766 SNP interrelates with ω-3 FAs changing serum adiponectin
levels and other inflammatory biomarkers [155,156].
On the other hand, two SNP located at APOE gene (rs7412 and rs429358) modify
apolipoprotein E mRNA codon 112 and 158, where cysteine is replaced by arginine in both
positions, and hence forms three possible isoforms of the protein according to the resultant
salt-bridges: ε2, ε3, and ε4 [158–161]. In this way, after eight weeks of a high-SFAs diet [162],
increased CRP levels was observed in APOE ε4 carriers (high risk allele). In the same way,
in the Food4Me study, the ε4 allele was associated with higher total cholesterol compared to
non-risk genotypes [161]. Additionally, a 16-week dietary intervention with a replacement
of 9.5% energy of MUFAs orω-6 FAs, reduced plasmatic CRP levels in APOE ε4 carriers,
while APOE ε3/ε3 carriers showed an opposite increment in CRP concentration [163].
Reports indicate that SNPs in CRP gene can change plasma CRP levels [164–166].
Additionally, higher intake of total PUFAs was associated with lower CRP levels, suggesting
reduced chronic systemic inflammation [167]. Additionally, greater adherence to the
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MedDiet and particularly its fish component was associated with lower CRP blood levels,
especially in those at highest genetic risk due to the CRP rs3093068 SNP [166]. Moreover,
SNPs in CRP gene modulated the risk of inflammation, which depends on individual
plasma fatty acid and lipid profile [168].
Recent data suggest that there is an association between fatty acid desaturase (FADS1-
3) SNPs and lipid composition in human blood and tissues [169]. A systematic review
identified that FADS SNPs may influence plasma and erythrocyte FA composition, as well
as T2DM risk markers, such as HOMA-IR and fasting glucose [170]. In the same way, the
presence of two common FADS haplotypes influences the ability to synthesize essentialω-3
andω-6 LC-PUFAs (e.g., ARA and DHA). Additionally, the haplotype D was associated
with increased FADS activity [171]. The FADS1 rs174537 SNP impacts the synthesis of
ARA and the overall capacity of whole blood to synthesize 5-lipoxygenase products [172].
Additionally, the rs174537T allele was associated with decrease in DGLA, ARA levels [173],
and diminished delta-5 desaturase enzyme activity, and FADS1 gene expression [174].
Another common FADS1 SNP, rs174550, modifies metabolic responses to an LA-enriched
diet (6% of total energy), influencing serum CRP and plasma fasting glucose levels and
ARA proportion in men [175]. Considering that FADS1 and FADS2 code for key enzymes
for the conversion of the ω-6 and ω-3 C18 FA to their respective C20 and C22 products,
SNPs in these genes could alter the viability of these products.
In the context of nutrigenetics, it is difficult to predict the impact that a variant may
have on the gene-diet interaction, especially because the genetic variation differs across
populations. For example, the frequency of FADS polymorphisms changes according to the
population, which could alter the efficiency ofω-6 and ω-3 in the diet [176]. The results of
the aforementioned studies suggest that the interaction between genetic factors, especially
SNPs, and dietary components can alter the response to nutritional interventions and,
consequently, susceptibility to several diseases.
Although we already know the gene-diet interaction, current strategies are based on
nutritional recommendations for populations in general, not considering the influence of
genetic factors on dietary components, such as lipids. Among the lipids-gene interaction
mentioned in this section, most studies have demonstrated a crosstalk betweenω-3 and ge-
netic polymorphisms, as evidenced in Table 3. In this sense, a genetic risk score constructed
from genes identified by genome association studies, partially explained the variation in
changes in TG in response to supplementation withω-3 FAs [5 g/day of fish oil (1.9–2.2 g
EPA and 1.1 g DHA daily)] [177]. This finding, added to the others previously mentioned
in this section, reinforces the importance of knowing the individual’s genetics background
for the prescription of nutritional supplementation.
In this context, precision nutrition is an important part of personalized medicine and
an emerging approach to disease prevention and treatment that takes genetic informa-
tion in consideration, as well as age, sex, pathophysiological status, and environmental
issues, including dietary patterns [178,179]. Nutritional prescriptions should consider the
diversity in the genetic background between individuals and ethnic groups, as it affects
nutritional needs, metabolism, and the response to nutritional and dietary interventions.
Thus, knowledge about nutrigenetics and nutrigenomics can allow health professionals
to decide on the most appropriate treatment to achieve precision nutrition, as well as
permitting the design of innovative strategies for the prevention, control, and treatment of
several diseases [176,179].
Although nutrigenomics is extremely important for the implementation of precision
nutrition, these studies still have limitations. First, several studies are still scarce and
heterogeneous, which makes it difficult to compare apparently similar studies that analyze
the same genetic variants and dietary components. Second, genomic data requires a
comprehensive analysis of bioinformatics, which makes it difficult to understand the
results. Third, it is necessary to integrate the results of several omics studies in order to
have more robust findings.
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Table 3. Gene-dietary fat interactions mediating inflammation and lipid metabolism. ↑ higher levels; ↓ lower levels.
Gene SNP Dietary Fat Interaction Main Results References
ADIPOQ rs2241766, rs16861209,rs17300539
SFA [C14:0 + C16:0 + EA],
MUFA [C16:1n-7 + AO],
PUFA [ω-6 PUFAs +ω-3
PUFAs], ω-6 [LA (18:2 n-6)
+ DGLA (20:3 n-6) + AA
(20:4n-6)], ω-3-HUFA
[EPA + DPA (22:5ω-3) +
DHA], and ω-3 [LA
(18:3n3) +ω-3 HUFA].
rs2241766G allele: ↑ total plasma
ω-3 FA content was protective
against inflammation.
Gene-plasma FA profile interaction:
rs2241766 andω-3; rs16861209 and




High-MUFA: total fat 38%,
carbohydrate 45% of
energy. MUFA intake of
20% of energy.
rs182052 G/G genotype: serum
adiponectin levels ↑ in 3.8% after a
high-MUFA diet. In these patients, a





ω-3 PUFA (fish oil
supplementation—daily
doses of 0.45, 0.9, and 1.8 g
20:5n3 and 22:6n3 (1.51:1),
or placebo).
rs17300539A allele: ↑ serum
adiponectin levels.
rs2241766 T/T genotype: subjects
aged >58y had a 22% ↑ in serum
adiponectin levels compared to
baseline after the highest dose of
20:5n3 and 22:6n3.
[156]
APOE rs429358, rs7412 SFA (Food4MeStudy)
APOE ε4 allele was associated with
higher total cholesterol. [161]
rs429358, rs7412
Low-fat diet (24% from fat,
8% from SFA, 59% from
carbohydrate), high-fat
high-SFA diet (38% from
fat, 18% from SFA, 45%
from carbohydrate), and
high-fat high-SFA diet
supplemented with 3.45 g
DHA/d
APOE ε4 carriers: ↑ CRP plasma
levels after eight weeks of a
high-SFA and high-SFA-DHA diets
relative to low-fat diet.
[162]
rs429358, rs7412 SFA with MUFA orω-6FA
Diet-genotype interaction:
differential responsiveness to MUFA
intake between ε3/ε3 and ε4
carriers.
[163]
CRP rs2808630, rs3093058,rs3093062 SFA and MUFA
Presence of rs3093058 and rs3093062
minor allele: ↑ CRP levels in the
presence of ↑ triglyceride or
cholesterol intake.
rs2808630 minor allele: ↑ intake of
SFA and MUFA, ↑ CRP levels.
Presence of the minor allele of these




CRP SNPs modulated the risk of
being in the inflammatory group





The minor allele of rs3093068 and
rs1130864: ↑ CRP levels
rs1205T allele: ↓ CRP concentrations.
Interaction between rs3093068 and
MedDiet.
[166]
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Table 3. Cont.







The presence of rs174537, rs174575,
and rs2727270 minor alleles: ↑ LA
levels
rs174537T and rs2727270T: ↓ DGLA
and ARA levels
rs1000778T allele: ↓ ARA levels
[173]
FADS
haplotype 28 closely linked SNPs ω-3 andω-6
Two common FADS haplotype differ




rs174537 impacts the synthesis of
ARA and the overall capacity of




rs174537T allele carriers: ↓ in 20:4
ω-6 levels, ↓ delta-5 desaturase




Habitual diet with a
supplement of 30, 40, or
50 mL (27–45 g) sunflower
oil (62% of LA) daily
depending on BMI
In men carrying the T/T genotype,
plasma eicosanoid concentrations
correlated with the ARA proportion
and with hsCRP. No correlations
were found for C/C genotype.
[175]
7. Dietary Lipids Modulate Gut Microbiota Composition and Metabolites Production
Microbial community in humans reaches the highest density and taxonomic diver-
sity in the gastrointestinal tract, with an estimation of 1014 microorganisms and almost
2000 different species of bacteria in the colon [180]. Owing its multifaceted crosstalk with
the host environment, the gut microbiota provides a range of beneficial properties to the
host, with a significant impact on human health and disease [181]. Research about the
gut microbiome has exponentially flourished in the last 20 years, providing also an in-
sight into the dissection of the impact of different dietary patterns on the gut microbiota
composition [182], including fats.
Despite most dietary FAs being absorbed in the small intestine, a certain percentage
can reach the colon, directly modulating the gut microbiota composition and function [183].
Indeed, FAs have been found to have an antimicrobial activity [184] and also represent a
substrate for bacteria [185], hence affecting gut metabolism and the host health.
Several animal studies investigated the impact of HFD enriched in SFAs (Table S1,
Supplementary Materials): while bacterial diversity and richness did not show signif-
icant changes, in most of the studies SFAs intake induced a significant increase in the
Firmicutes/Bacteroidetes ratio, which has been associated with obesity [186]. Negative
effects of SFAs on the microbiota composition included the decrease in Bifidobacterium, a
beneficial probiotics genus [187], the increase in Clostridium, a genus that also includes
pathogenic strains [188], and the increase in Bilophila wadsworthia, a sulphide-producer bac-
teria, which has been associated with immune and metabolic impairments [189]. However,
an increase in Ruminococcaceae, butyrate producing bacteria [190], has also been observed.
Some studies also evidenced that a HFD leaded to gut-barrier alterations and consequent
inflammation and gut-related disease [191–193].
Preliminary results from in vivo studies showed that a high intake of CC [194] or
rapeseed oil [195], rich in medium-chain fatty acids (MCFAs), has a positive impact on
gut microbiota in comparison to a diet rich in long-chain FAs, suggesting that the SFAs’
chemical structure (e.g., in the length of FAs chains) may differentially affect the microbiota
composition [195].
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Since it is well known that trans-FAs, originated from hydrogenated vegetable oils,
contribute to the development of chronic diseases [196], two recent studies investigated
their impact also on animals’ gut microbiota (Table S2, Supplementary Materials). They
demonstrated that trans-FAs induce adverse effects, decreasing Bacteroidetes and increas-
ing Firmicutes and Proteobacteria abundance [197,198], the latter considered a signature of
dysbiosis [199]; also, the families Ruminococcaceae, Lachnospiraceae, and Rikenellaceae
were significantly reduced in mice that consumed hydrogenated soybean oil [197], sup-
porting the hypothesis of a negative impact of trans-FAs on the gut microbiota composition
and on health.
A few studies investigated the effect of MUFAs on the gut microbiota composition
in animal models (Table S3, Supplementary Materials), suggesting an opposite effect
than SFAs. In particular, MUFAs were associated with an increase in Bacteroidetes and a
decrease in Firmicutes.
More data are available on PUFAs’ effect (bothω-3 andω-6, respectively described
in Tables S4 and S5 Supplementary Materials). Overall, the regular consumption of ω-3
has been associated with a condition of eubiosis, increasing probiotic bacteria such as Bifi-
dobacterium, Lactobacillus, and Akkermansia [200–203] and SCFAs-producer families, such as
Ruminococcaceae and Lachnospiraceae [200]. On the contrary, in vivo studies, whereω-6
PUFAs were supplemented, showed a decrease in Bifidobacterium and Lactobacillus [192,204]
and an increase in Clostridium [202,204], Firmicutes, and Proteobacteria [193].
Regarding studies on dietary lipids intake and gut microbiota in humans, a recent
systematic review [205] analyzed and compared observational and interventional studies.
Although the latter did not provide evidence of correlation between dietary fat intake
and gut microbiota composition, observational studies evidenced interesting metabolic
associations. Both types of studies showed a significant decrease in bacterial diversity
and richness in participants consuming HFD enriched in SFAs. Differentially, a MUFAs-
enriched diet reduced the number of total bacteria and PUFAs-enriched diet did not induce
any significant change in richness, diversity, and total number of bacteria [205]. Results
from observational studies demonstrated positive correlations between (i) SFAs intake and
bacterial genera such as Blautia and Clostridium, (ii) MUFAs intake and Blautia, (iii) PUFAs
intake and Tenericutes, the latter associated with lower TG in plasma. The higher ratio
Firmicutes/Bacteroidetes in subjects consuming SFAs is in accordance with results from
studies in mice and correlated with obesity and inflammatory conditions. On the contrary,
this effect was not found in participants consuming diets enriched in MUFAs or PUFAs.
For an in depth description, see [205–207].
Although most studies have been conducted in animals and results are still not
consistent, interesting findings are revealing, suggesting that HFD rich in SFAs exerts
negative effects on the gut microbiota with consequences on human metabolism and
health [208]; a diet rich in PUFAs may have a positive effect on microbial communities in
human gut, supporting the beneficial role of these essential and anti-inflammatory dietary
components on human health. On the contrary, effects of a diet rich in MUFAs on the
gut microbiome composition are still inconclusive. Further studies might support the
promising, but still complex, design of personalized diets able to modulate the microbiota
composition also through the effect of specific FAs.
8. Conclusions
Plant- and animal-derived food differ in dietary lipid content and quality associated
chemical characteristics, as well as for the presence of additional bioactive compounds
and/or nutrients that contribute to the final effect on gene expression regulation (i.e.,
the nutrigenomic effect) (Figure 3). The chemical structure of lipids influences also their
oxidative stability contributing to produce secondary metabolites with various impact
on molecular responses. Research on animal models highlights how the type of FAs,
their amount, and the time of exposure to a fat-rich diet can modulate cellular responses
mediated by regulating gene expression, and significantly contributing to describe the
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nutrigenomic role of dietary lipids. However, going toward human studies, the picture
becomes more complex, also because of the contribution of the individual genetic variability
and the gut microbiota diversity. According to the gene-dietary fat interaction, SNPs
contribute to produce multifaceted molecular responses, that may differ from outcomes
obtained in vitro and/or in preclinical studies. Results from animal and human studies on
gut microbiota composition partially contribute to characterize the response associated to
dietary fat intake.
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A major strength of the research production in this area relies on the specific contri-
bution to describing the complex impact of dietary lipids on gene expression regulation.
However, a major weakness in the characterization of this multifaceted picture still exists,
especially in humans. This is at least partially due to the wide extent of the human ge-
netic variability, which generates a plethora of different phenotypes, with heterogeneous
responses to dietary factors, including lipids. The incorporation of nutrigenetic data into
human studies might help to reduce this confounding factor. Genomics might be used
for Mendelian randomization studies aimed to demonstrate causal effects of lipids on
human health and diseases, reducing confounding and reverse causation [209]. Finally,
a better understanding of the role of the microbiome and of metabolites that it produces
(still only partially characterized because of the complexity of the system and the large
inter-individual variations) might help to elucidate how it modulates the effect of dietary
lipids in each individual.
In conclusion, to properly define the exact individual response to dietary lipids, the
research on the nutrigenomics of dietary lipids urgently needs the confluence of omics
domains (i.e., nutrigenomics, nutri-epigenetics, nutrigenetics, metabolomics, especially
lipidomics, etc.) [210], which will strongly improve the possibility to translate this knowl-
edge into clinical practice.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/antiox10070994/s1, Table S1: The impact of HFD rich in saturated fats on gut microbiota
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composition in animals, Table S2: The impact of TFA (trans fatty acids) on gut microbiota compo-
sition in animals, Table S3: The impact of MUFA (monounsaturated fatty acids) on gut microbiota
composition in animals, Table S4: The impact of PUFA-n-3 (polyunsaturated fatty acids-omega3) on
gut microbiota composition in animals, Table S5: The impact of PUFA-n-6 (polyunsaturated fatty
acids-omega6) on gut microbiota composition in animals.
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Abbreviations
AD Alzheimer’s disease
ADIPOQ Adiponectin, C1Q and collagen domain containing
ALA α-Linolenic acid
AMPK 5′AMP-activated protein kinase
ARA Arachidonic acid
CO Coconut oil





DGLA Dihomo gamma-linolenic acid
EPA Eicosapentaenoic acid
EA Estearic acid
EVOO Extra virgin olive oil
FAs Fatty acids
FADS Fatty acid desaturase
FFAs Free fatty acids
GFAP Glial fibrillary acidic protein




HUFA Highly unsaturated fatty acid
IFNγ Interferon γ
IL Interleukine
IRF3 Interferon regulatory factor 3
LA Linoleic acid




LXRA Liver X receptor-alpha
MAPK Mitogen-activated protein kinase
MCP-1 Monocyte chemoattractant protein-1
MCFAs Medium chain fatty acids
MedDiet Mediterranean diet
MUFAs Monounsaturated fatty acids
MyD88 Myeloid differentiation primary response 88
NADPH Nicotinamide adenine dinucleotide phosphate
NAFLD Non-alcoholic fatty liver disease
NF-κB Nuclear factor kappa B
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NLRP3 Nucleotide-binding and oligomerization domain–like receptor, leucine-rich repeat and
pyrin domain–containing 3 inflammasome
NRF2 Nuclear factor erythroid 2-related factor 2
OA Oleic acid




PPAR-γ Peroxisome proliferator-activated receptor γ
PUFAs Polyunsaturated fatty acids
ROS Reactive oxygen species
SCFAs Short chain fatty acids
SCI Systemic chronic inflammation
SFAs Saturated fatty acids
SNPs Single nucleotide polymorphisms
SOD Superoxide dismutase
SREBPs Sterol regulatory element binding proteins
T2DM Type 2 diabetes mellitus
TG Triglycerides
TLRs Toll-like receptors
TNFα Tumor necrosis factor α
TXs Thromboxanes
ω-3 Omega-3 fatty acids
ω-6 Omega-6 fatty acids
USF1 Upstream transcription factor 1
UCP2 Uncoupling protein 2
VEGF Vascular endothelial growth factor
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